0000950170-21-004908 | 10-Q | XBRL Viewer

Print Document View Excel Document

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Expenses:
Research and development	$ 6,365	$ 2,850	$ 17,182	$ 14,499
General and administrative	2,530	781	6,441	2,798
Total operating expenses	8,895	3,631	23,623	17,297
Total operating loss	8,895	3,631	23,623	17,297
Other income (expense):
Change in fair value of warrant liability			(1)
Change in fair value of derivative liability	52
Interest income (expense), including amortization of discount	5		8	(2)
Loss from disposal of assets			(3)
Total other income (expense)	57		6	(2)
Net loss and comprehensive loss	(8,838)	(3,631)	(23,617)	(17,299)
Net loss attributable to common stockholders - basic and diluted	$ (12,506)	$ (5,579)	$ (33,244)	$ (23,101)
Net loss per share attributable to common stockholders—basic and diluted	$ (28.33)	$ (14.81)	$ (77.93)	$ (63.69)
Weighted average common stock outstanding- basic and diluted	441,448	376,738	426,604	362,735

Income Taxes	9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2021 as the Company incurred losses for the nine months ended September 30, 2021, and is forecasting additional losses through the remainder of fiscal year ending December 31, 2021, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2021. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method. Due to the Company’s history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company does not currently believe that realization of its deferred tax assets is more likely than not. As of September 30, 2021, the Company had no unrecognized income tax benefits that would reduce the Company’s effective tax rate if recognized.

Income Taxes

9 Months Ended

Sep. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

14. Income Taxes

The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2021 as the Company incurred losses for the nine months ended September 30, 2021, and is forecasting additional losses through the remainder of fiscal year ending December 31, 2021, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2021. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method.

Due to the Company’s history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company does not currently believe that realization of its deferred tax assets is more likely than not.

As of September 30, 2021, the Company had no unrecognized income tax benefits that would reduce the Company’s effective tax rate if recognized.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Series B Warrants - Summary of Estimated Fair Value of Warrants and Significant Assumptions (Details) - Series B Warrants	Dec. 30, 2021	Sep. 30, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (years)		3 years 6 months
Scenario Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (years)	4 years 2 months 12 days
Series B Estimated Fair Value
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input		1.12
Series B Estimated Fair Value \| Scenario Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	1.17
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input		79.50
Volatility \| Scenario Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	74.07
Risk Free Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input		0.76
Risk Free Rate \| Scenario Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.27
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input		7.00
Dividend yield \| Scenario Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	7.00

Series B Warrants - Additional Information (Details) - Series B Warrants - $ / shares	1 Months Ended
	May 31, 2015	Feb. 28, 2015	Nov. 02, 2021	Sep. 30, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Warrants outstanding				173,827	173,827
Common Stock Warrants \| Subsequent Event
Class Of Warrant Or Right [Line Items]
Number of Warrants converted			12,686
Series B Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants converted	887,536	1,650,098
Exercise price of warrants	$ 1.24235	$ 1.24235
Warrants expiration period	10 years	10 years

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Depreciation expense	$ 200	$ 200	$ 601	$ 605

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2021

Leases [Abstract]

Summary of Lease Costs

The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s leases for the three and nine months ended September 30, 2021 (in thousands):


	Three Months Ended September 30, 2021		Nine Months Ended September 30, 2021
Lease Cost
Financing lease costs:
Amortization of finance right-of-use assets	$	-	$	11
Operating lease costs		154		370
Variable lease costs		90		233
Total lease costs	$	244	$	614


Cash paid for amounts included in the measurement of lease liability—finance leases	$	15
Cash paid for amounts included in the measurement of lease liability—operating leases	$	367
Weighted-average remaining lease term—operating leases (years)		1.83
Weighted-average discount rate—finance leases		7.94	%
Weighted-average discount rate—operating leases		3.51	%

Summary of Future Minimum Commitments of Operating Lease Liabilities

The following table reconciles the future minimum commitments to the Company’s operating lease liabilities at September 30, 2021 (in thousands):


	Operating lease payments as of September 30, 2021
2021 (excluding nine months ended September 30, 2021)	$	153
2022		625
2023		377
Total lease payments		1,155
Less: interest		(35	)
Total operating lease liabilities at September 30, 2021		1,120
Less: current portion of lease liabilities		607
Lease liabilities, net of current portion	$	513

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 6,975	$ 5,926
Less—accumulated depreciation	(2,533)	(2,352)
Property and equipment, net	4,442	3,574
Assets Under Construction
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,741	1,154
IT Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	73
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	13
Lab Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,085	4,708
Office Furniture
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 63	$ 64

Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Series A Convertible Preferred Stock	Series A-1 Convertible Preferred Stock	Series A-2 Convertible Preferred Stock	Series B Convertible Preferred Stock	Series C-1 and C-2 Convertible Preferred Stock	Series D-1 and D-2 Convertible Preferred Stock	Series E Convertible Preferred Stock
Beginning Balance at Dec. 31, 2019	$ (87,406)		$ 7,274	$ (94,680)
Convertible preferred stock, Beginning Balance at Dec. 31, 2019					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 39,686
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2019					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	57,878,742
Beginning Balance, Shares at Dec. 31, 2019		340,591
Stock-based compensation expense	177		177
Stock option exercises	33		33
Stock option exercises, Shares		7,880
Net loss	(7,512)			(7,512)
Ending Balance at Mar. 31, 2020	(94,708)		7,484	(102,192)
Convertible preferred stock, Ending Balance at Mar. 31, 2020					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 39,686
Convertible preferred stock, Ending Balance, Shares at Mar. 31, 2020					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	57,878,742
Ending Balance, Shares at Mar. 31, 2020		348,471
Beginning Balance at Dec. 31, 2019	(87,406)		7,274	(94,680)
Convertible preferred stock, Beginning Balance at Dec. 31, 2019					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 39,686
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2019					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	57,878,742
Beginning Balance, Shares at Dec. 31, 2019		340,591
Net loss	(17,299)
Ending Balance at Sep. 30, 2020	(104,000)		7,979	(111,979)
Convertible preferred stock, Ending Balance at Sep. 30, 2020					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 39,686
Convertible preferred stock, Ending Balance, Shares at Sep. 30, 2020					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	57,878,742
Ending Balance, Shares at Sep. 30, 2020		379,902
Beginning Balance at Mar. 31, 2020	(94,708)		7,484	(102,192)
Convertible preferred stock, Beginning Balance at Mar. 31, 2020					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 39,686
Convertible preferred stock, Beginning Balance, Shares at Mar. 31, 2020					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	57,878,742
Beginning Balance, Shares at Mar. 31, 2020		348,471
Stock-based compensation expense	189		189
Stock option exercises	97		97
Stock option exercises, Shares		24,648
Net loss	(6,156)			(6,156)
Ending Balance at Jun. 30, 2020	(100,578)		7,770	(108,348)
Convertible preferred stock, Ending Balance at Jun. 30, 2020					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 39,686
Convertible preferred stock, Ending Balance, Shares at Jun. 30, 2020					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	57,878,742
Ending Balance, Shares at Jun. 30, 2020		373,119
Stock-based compensation expense	191		191
Stock option exercises	18		18
Stock option exercises, Shares		6,783
Net loss	(3,631)			(3,631)
Ending Balance at Sep. 30, 2020	(104,000)		7,979	(111,979)
Convertible preferred stock, Ending Balance at Sep. 30, 2020					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 39,686
Convertible preferred stock, Ending Balance, Shares at Sep. 30, 2020					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	57,878,742
Ending Balance, Shares at Sep. 30, 2020		379,902
Beginning Balance at Dec. 31, 2020	(108,713)		8,173	(116,886)
Convertible preferred stock, Beginning Balance at Dec. 31, 2020					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 49,593
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2020					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	72,348,452	0
Beginning Balance, Shares at Dec. 31, 2020		381,123
Issuance of convertible preferred stock										$ 6,982	$ 80,246
Issuance of convertible preferred stock, Shares										10,128,771	102,671,041
Stock-based compensation expense	185		185
Stock option exercises	265		265
Stock option exercises, Shares		54,296
Net loss	(5,927)			(5,927)
Ending Balance at Mar. 31, 2021	(114,190)		8,623	(122,813)
Convertible preferred stock, Ending Balance at Mar. 31, 2021					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 56,575	$ 80,246
Convertible preferred stock, Ending Balance, Shares at Mar. 31, 2021					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	82,477,223	102,671,041
Ending Balance, Shares at Mar. 31, 2021		435,419
Beginning Balance at Dec. 31, 2020	(108,713)		8,173	(116,886)
Convertible preferred stock, Beginning Balance at Dec. 31, 2020					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 49,593
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2020					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	72,348,452	0
Beginning Balance, Shares at Dec. 31, 2020		381,123
Net loss	(23,617)
Ending Balance at Sep. 30, 2021	(131,015)		9,488	(140,503)
Convertible preferred stock, Ending Balance at Sep. 30, 2021					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 56,575	$ 80,246
Convertible preferred stock, Ending Balance, Shares at Sep. 30, 2021					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	82,477,223	102,671,041
Ending Balance, Shares at Sep. 30, 2021		442,717
Beginning Balance at Mar. 31, 2021	(114,190)		8,623	(122,813)
Convertible preferred stock, Beginning Balance at Mar. 31, 2021					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 56,575	$ 80,246
Convertible preferred stock, Beginning Balance, Shares at Mar. 31, 2021					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	82,477,223	102,671,041
Beginning Balance, Shares at Mar. 31, 2021		435,419
Stock-based compensation expense	271		271
Stock option exercises	20		20
Stock option exercises, Shares		3,649
Net loss	(8,852)			(8,852)
Ending Balance at Jun. 30, 2021	(122,751)		8,914	(131,665)
Convertible preferred stock, Ending Balance at Jun. 30, 2021					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 56,575	$ 80,246
Convertible preferred stock, Ending Balance, Shares at Jun. 30, 2021					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	82,477,223	102,671,041
Ending Balance, Shares at Jun. 30, 2021		439,068
Stock-based compensation expense	554		554
Stock option exercises	20		20
Stock option exercises, Shares		3,649
Net loss	(8,838)			(8,838)
Ending Balance at Sep. 30, 2021	$ (131,015)		$ 9,488	$ (140,503)
Convertible preferred stock, Ending Balance at Sep. 30, 2021					$ 3,368	$ 7,837	$ 5,373	$ 20,806	$ 41,099	$ 56,575	$ 80,246
Convertible preferred stock, Ending Balance, Shares at Sep. 30, 2021					1,701,141	3,298,732	4,324,998	22,531,819	91,327,903	82,477,223	102,671,041
Ending Balance, Shares at Sep. 30, 2021		442,717

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued research and development expenses	$ 1,184	$ 750
Accrued compensation	1,569	1,023
Other	735	277
Accrued expenses and other current liabilities	$ 3,488	$ 2,050

Compensation

9 Months Ended

Sep. 30, 2021

Compensation And Retirement Disclosure [Abstract]

Compensation

11. Compensation

In January 2012, the Company adopted the Aura Biosciences 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”) for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company makes matching contributions of 100% of the first 6% of employee contributions. The Company made matching contributions in the amount of $0.2 million and $0.1 million for the nine months ended September 30, 2021 and 2020, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Series D Tranche 2 Convertible Preferred Stock
Stock issuance cost, net	$ 18
Series E Convertible Preferred Stock
Stock issuance cost, net	$ 237

Convertible Preferred Stock

9 Months Ended

Sep. 30, 2021

Temporary Equity Disclosure [Abstract]

Convertible Preferred Stock

7. Convertible Preferred Stock

As of September 30, 2021, the Company had 1,701,141 authorized, issued and outstanding shares of Series A Preferred stock, par value $0.00001, or the Series A, 3,298,732 authorized, issued and outstanding shares of Series A-1 Preferred stock, par value $0.00001, or the Series A-1, 4,325,021 authorized shares and 4,324,998 issued and outstanding shares of Series A-2 Preferred stock, par value $0.00001, or the Series A-2, and 22,705,646 authorized shares and 22,531,819 issued and outstanding shares of Series B Preferred stock, par value $0.00001, or the Series B, 58,109,711 authorized, issued and outstanding shares of Series C-1 Preferred stock, par value $0.00001, or the Series C-1, 33,218,192 authorized, issued and outstanding shares of Series C-2 Preferred stock, par value $0.00001, or the Series C-2, together with Series C-1, the Series C, 57,878,742 authorized, issued and outstanding shares of Series D-1 Preferred stock, par value $0.00001, or the Series D-1, and 24,598,481 authorized, issued and outstanding shares of Series D-2 Preferred stock, par value $0.00001, or the Series D-2, together with the Series D-1, the Series D, 102,671,041 authorized, issued, and outstanding shares of Series E Preferred stock, par value $0.00001, or the Series E, and together with the Series D, the Series C and the Series B, collectively the Senior Preferred Stock. All series of convertible preferred stock are collectively referred to as the Preferred Stock, each with a par value of $0.00001 per share.

Series D-2 Offering

On June 25, 2020, the Company entered into a Series D-2 Convertible Preferred Stock Purchase Agreement, or the Series D-2 Agreement, with certain investors to sell up to 24,598,481 shares of the Series D-2 stock at a purchase price of $0.6911 per share. The Series D-2 Agreement provides for two closings, the first on October 1, 2020, and the second upon the achievement or waiver of certain milestone events. The Company sold 14,469,710 shares of the Series D-2 on October 1, 2020, at the first tranche closing for gross proceeds of $10.0 million.

On March 5, 2021, the Company completed the second tranche of the Series D-2 offering and issued 10,128,771 shares of the Series D-2 at a purchase price of $0.6911 per share for gross proceeds of $7.0 million.

Costs incurred in connection with the Series D-2 offering totaled $0.1 million and were recorded as a reduction of proceeds from the Series D-2. The majority of offering costs were incurred during the year ended December 31, 2020. Offering costs incurred during the nine months ended September 30, 2021, were $0.02 million.

Series E Offering

On March 18, 2021, the Company completed its Series E offering and issued 102,671,041 shares of Series E stock, $0.00001 par value per share, at a purchase price of $0.7839 per share for gross proceeds of $80.5 million.

Costs incurred in connection with the Series E offering totaled $0.2 million during the nine months September 30, 2021 and were recorded as a reduction to the Series E convertible preferred stock.

The rights and privileges of the Company’s Preferred Stock are as follows:

Voting

Except as otherwise required by law or by other provisions, holders of the Preferred Stock vote together with the holders of common stock as a single class. Holders of the Preferred Stock may cast the number of votes equal to the number of shares of common stock to which such shares of the Preferred Stock are convertible into.

Dividends

Series C, D, and E Dividends:

From and after the date of the issuance of any shares of the Series C-1, Series C-2, Series D-1, Series D-2, and Series E, dividends at the annual rate of seven percent (7%) per annum of the original share price per share accrue on such shares of the Series C-1, Series C-2, Series D-1, Series D-2, and Series E. Dividends accrue from day to day, whether or not declared, and are cumulative, but not compounding. Such dividends are only payable when and if declared by the Board of Directors (the "Board") or in the event of a Deemed Liquidation Event (as defined in the amended and restated Certificate of Incorporation). No other dividends may be declared or paid on any other class of stock unless the holders of the shares of the Series E then outstanding first receive, or simultaneously receive, their applicable dividend. As of September 30, 2021, $7.4 million, $3.2 million, $6.0 million, $1.0 million, and $3.0 million of cumulative dividends on the Series C-1, Series C-2, Series D-1, Series D-2, and Series E respectively, are included in the liquidation preference amount indicated on the balance sheet.

Series B Dividends:

From and after the date of the issuance of any shares of the Series B, dividends at the annual rate of $0.0869645 per share accrue on such shares of the Series B. Dividends accrue from day to day, whether or not declared, and are cumulative, but not compounding. Such dividends are only payable when and if declared by the Company’s Board or in the event of a Deemed Liquidation Event (as defined in the amended and restated Certificate of Incorporation). No other dividends may be declared or paid on any other class of stock unless the holders of the shares of the Series B then outstanding first receive, or simultaneously receive, their applicable dividend. As of September 30, 2021, $10.9 million of cumulative dividends on the Series B are included in the liquidation preference amount indicated on the balance sheet.

Series A Dividends

From and after the date of the issuance of the Series A, Series A-1, and Series A-2, if the Company declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Company, the dividend payable to the holders of the Series A, Series A-1, and Series A-2 convertible preferred stock shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest dividend. No other dividends, or dividends on common stock payable in shares of common stock, may be declared or paid unless the holders of the Series A, Series A-1, and Series A-2 then outstanding first receive, or simultaneously receive, their applicable dividend. As of September 30, 2021, no dividends have been declared on the common stock or the Preferred Stock.

Liquidation Rights

In the event of a Deemed Liquidation Event, as defined in the Company’s amended and restated Certificate of Incorporation, the assets of the Company will be distributed first to the holders of the Series E. The holders of the Series E will receive, in preference to all other stockholders, an amount equal to the sum of the Series E original issue price (equal to the cash price paid per share of $0.783900), plus unpaid dividends on such shares. Next, the holders of the Series D will receive, in preference to all other stockholders other than the Series E, an amount equal to the sum of the Series D original issue price, plus unpaid dividends on such shares. Next, the holders of the Series C will receive, in preference to all stockholders other than the Series E and D holders, an amount equal to the sum of the Series C original issue price plus unpaid dividends on such shares. Next, the holders of the Series B will receive, in preference to the holders of the Series A, Series A-1, Series A-2 and common stock, an amount equal to the sum of the Series B original issue price plus unpaid dividends on such shares. Next, the holders of the Series A, Series A-1, and Series A-2 will receive, in preference to the holders of common stock, an amount equal to the greater of their applicable liquidation preference or what they would have received had their shares converted into common stock. If the proceeds available are not sufficient to satisfy the full liquidation preference, the entire proceeds are to be distributed pro-rata among the Series E holders in proportion to the full preferential amount the Series E holders are entitled to receive.

Conversion

The Senior Preferred Stock converts into common stock on a one-for-one basis. Each share of the Series B, Series C-1, Series C-2, Series D-1, Series D-2, and Series E is convertible into the number of shares of common stock as is determined by dividing the respective original issue price by the conversion price in effect at the time of conversion. The Series E conversion price is set at $0.7839 per share, the Series D-1 and Series D-2 conversion price is set at $0.6911 per share, the Series C-1 conversion price is set at $0.5213 per share, the Series C-2 conversion price is set at $0.36491 per share, and the Series B conversion price is set at $1.24235 per share; none represents a beneficial conversion feature. Subject to certain exceptions, the Senior Preferred Stock has the benefit of anti- dilution protection on a weighted-average basis in the event that the Company sells stock at less than the applicable conversion price per share.

Each share of the Series A and Series A-1 was originally convertible into the number of shares of common stock determined by dividing the respective Series A and Series A-1 original issue price by the conversion price in effect at the time of conversion. The Series A conversion price was originally equal to $2.00 per share and the Series A-1 conversion price was originally equal to $2.4847 per share. As the Series A-2 was sold at $1.24235 per share, less than the per share prices of the Series A and Series A-1, anti-dilution protections were triggered. Pursuant to the anti-dilution protection terms, on February 24, 2015, the Series A conversion price was reduced from $2.00 to $1.8191 per share of common stock and the Series A-1 conversion price was reduced from $2.4847 to $2.1898 per share of common stock and, therefore, the Series A conversion ratio was changed from 1 to 1 to 1 to 1.099 and the Series A-1 conversion ratio was changed from 1 to 1 to 1 to 1.135. The Company evaluated the Series A and Series A-1 with the updated conversion ratios and determined that there was no beneficial conversion feature.

The Series A-2 converts into common stock on a one-for-one basis. The Series A-2 conversion price is set at $1.24235 per share and does not represent a beneficial conversion feature.

According to the terms of the Company’s amended and restated Certificate of Incorporation, in the event that the applicable conversion price for any series of Senior Preferred Stock is reduced, then the applicable conversion price for each series of the Series A convertible preferred stock shall be uniformly and concurrently reduced.

Each share of the Preferred Stock will automatically convert into common stock upon (a) the occurrence of an event, specified by vote or written consent of certain stockholders or (b) the completion of a public stock offering involving a price per share of common stock of not less than $1.554975 per share, subject to certain adjustments, where such offering results in aggregate gross proceeds to the Company of at least $50.0 million and the common stock is listed for trading on either the New York Stock Exchange or the Nasdaq Stock Market.

The Company must reserve and keep available out of its authorized but unused capital stock such number of authorized shares of common stock to sufficiently effect the conversion of all outstanding Preferred Stock.

In considering the features of the convertible preferred stock, the Company determined that none of the features, including the conversion features, requires bifurcation during the nine months ended September 30, 2021 and 2020.

The conversion ratios for the Series A was changed to 13.700 to 1.099, Series A-1 was changed to 13.7 to 1.135 , and the Series A-2 through the Series E was changed to 13.7 to 1 upon the Company’s filing of its amendment to its amended and restated Certificate of Incorporation on October 22, 2021 (see Note 16).

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jan. 01, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred offering costs	$ 1,600
Operating lease liabilities	1,120
Operating lease right of use assets	$ 1,096
Deferred rent			$ 8
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]			true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2021
Operating lease liabilities		$ 600
Operating lease right of use assets		500
Deferred rent		$ 20
Change in accounting principle, accounting standards update, immaterial effect [true false]		true

- Definition

Indicates (true false) whether accounting standards update was adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S65
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)

Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

+ Details

- Definition

Date accounting standards update was adopted, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S65
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

+ Details

Fair Value of Assets and Liabilities - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Assets transfers into Level 3	$ 0	$ 0
Assets, transfers out of Level 3	0	0
Liability, transfers into Level 3	0	0
Liability, transfers out of Level 3	$ 0	$ 0

Commitments and Contingencies- Schedule of Fair Value of Financial Assets and Liabilities (Details) $ in Thousands	Sep. 30, 2021 USD ($)
Leases [Abstract]
2021 (excluding nine months ended September 30, 2021)	$ 153
2022	625
2023	377
Total lease payments	1,155
Less: interest	(35)
Total operating lease liabilities at September 30, 2021	1,120
Less: current portion of lease liabilities	607
Lease liabilities, net of current portion	$ 513

Prepaid Expenses and Other Current Assets

9 Months Ended

Sep. 30, 2021

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid Expenses and Other Current Assets

5. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30, 2021		December 31, 2020
Prepaid insurance	$	80	$	51
Prepaid research and development expenses		1,474		976
Other		55		16
Prepaid expenses and other current assets	$	1,609	$	1,043

Commitments and Contingencies - Summary of Lease Costs (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021 USD ($)	Sep. 30, 2021 USD ($)
Leases [Abstract]
Amortization of finance right-of-use assets		$ 11
Operating lease costs	$ 154	370
Variable lease costs	90	233
Total lease costs	$ 244	614
Cash paid for amounts included in the measurement of lease liability—finance leases		15
Cash paid for amounts included in the measurement of lease liability—operating leases		$ 367
Weighted-average remaining lease term—operating leases (years)	1 year 9 months 29 days	1 year 9 months 29 days
Weighted-average discount rate—finance leases	7.94%	7.94%
Weighted-average discount rate—operating leases	3.51%	3.51%

Net Loss Per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	25,728,196	14,686,345	25,728,196	14,686,345
Convertible Preferred Stock on as if Converted Basis
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	22,550,561	13,260,868	22,550,561	13,260,868
Stock Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	3,164,949	1,412,791	3,164,949	1,412,791
Warrants to Purchase Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	12,686	12,686	12,686	12,686

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. In management’s opinion, the accompanying unaudited condensed financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying condensed balance sheet as of September 30, 2021, the condensed statements of operations and comprehensive loss, condensed statement of convertible preferred stock and stockholders’ deficit for the three and nine months ended September 30, 2021 and 2020, and the condensed statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2021 and the results of its operations for the three and nine months ended September 30, 2021 and 2020 and its cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are also unaudited. The unaudited condensed results of operations are not necessarily indicative of the operating results that may occur for the full fiscal year ending December 31, 2021. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission, or the SEC. Management believes that the disclosures provided here are adequate to make the information presented not misleading when these unaudited condensed financial statements are read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2020. The balance sheet data as of December 31, 2020 was derived from the Company’s audited financial statements included in the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on November 1, 2021.
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2020, filed with the SEC as a part of the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on November 1, 2021. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies except as noted below.
Cash Equivalents	Cash Equivalents Cash equivalents are highly liquid investments with an original maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds that invest in U.S. Treasury obligations and government funds with commercial banks and financial institutions.
Leases	Leases Prior to January 1, 2021, the Company accounted for leases in accordance with ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalation, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was charged to deferred rent. The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature within the proceeding twelve months. Effective January 1, 2021, the Company accounts for leases in accordance with ASU No. 2016-02, Leases (Topic 842) (“ASC 842”). At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. For each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability. The Company adopted the new leasing standard effective January 1, 2021, using the modified retrospective transition approach which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. ASC 842 provides several optional practical expedients in transition. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. The Company elected the practical expedient to not separate lease and non-lease components for all classes of underlying assets and therefore measures each lease payment as the total of the fixed lease and associated non-lease components. Lease liabilities are measured at lease commencement and calculated as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. If an implicit rate is not readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. Right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor. The lease term is measured as the noncancelable period in the contract, adjusted for any options to extend or terminate when it is reasonably certain the Company will extend the lease term via such options based on an assessment of economic factors present as of the lease commencement date. The Company elected the practical expedient to not recognize leases with a lease term of twelve months or less. Components of a lease are split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) are allocated, based on the respective relative fair values, to the lease components and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. The Company’s operating leases are presented in the condensed balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. As of September 30, 2021, the Company had deferred offering costs of $1.6 million.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Upon adoption of ASC 842, the Company recorded lease liabilities and their corresponding right-of-use assets based on the present value of lease payments over the remaining lease term. The adoption of ASC 842 resulted in the recognition of operating lease liabilities of $0.6 million and operating lease right-of-use assets of $0.5 million and the derecognition of deferred rent liabilities of $0.02 million on the Company’s balance sheet as of January 1, 2021. The adoption impact relates to the Company’s existing operating lease for operating and laboratory space. The adoption of ASC 842 did not have a material impact on the Company’s statements of operations and comprehensive loss or statements of cash flows.

Series B Warrants

9 Months Ended

Sep. 30, 2021

Equity [Abstract]

Series B Warrants

10. Series B Warrants

In February 2015 and May 2015, the Company issued warrants to purchase 1,650,098 and 887,536 shares of the Series B convertible preferred stock, respectively, at an exercise price of $1.24235 per share. Each Series B Warrant was immediately exercisable and expires in ten years from the original date of issuance. Pursuant to FASB ASC Topic 480, Distinguishing Liabilities from Equity, the Series B Warrants were classified as a liability and are re-measured to fair value at each balance sheet date and immediately prior to exercise. The Series B Warrants were converted into warrants to purchase 12,686 shares of common stock upon the completion of the IPO in November 2021.

A total of 173,827 of the Series B Warrants remained outstanding at September 30, 2021 and December 31, 2020.

The warrants were valued using the Black-Scholes option pricing model. The estimated fair value of the warrants and the significant assumptions used were as follows:


Series B Warrants	September 30, 2021			December 30, 2021
Series B estimated fair value	$	1.12		$	1.17
Volatility		79.50	%		74.07	%
Expected term (years)		3.5			4.2
Risk free rate		0.76	%		0.27	%
Dividend yield		7.00	%		7.00	%

During the nine months ended September 30, 2021, the change in fair value of the warrant liability was deemed immaterial.

Convertible Preferred Stock - Additional Information (Details)				3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 18, 2021 USD ($) $ / shares shares	Mar. 05, 2021 USD ($) $ / shares shares	Oct. 01, 2020 USD ($) shares	Mar. 31, 2021 USD ($) shares	Sep. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Oct. 22, 2021	Jun. 30, 2021 shares	Sep. 30, 2020 shares	Jun. 30, 2020 shares	Jun. 25, 2020 $ / shares shares	Mar. 31, 2020 shares	Dec. 31, 2019 shares
Temporary Equity [Line Items]
Convertible preferred stock, par value \| $ / shares					$ 0.00001
Common stock dividends declared \| $					$ 0
Preferred stock liquidation rights description					In the event of a Deemed Liquidation Event, as defined in the Company’s amended and restated Certificate of Incorporation, the assets of the Company will be distributed first to the holders of the Series E. The holders of the Series E will receive, in preference to all other stockholders, an amount equal to the sum of the Series E original issue price (equal to the cash price paid per share of $0.783900), plus unpaid dividends on such shares. Next, the holders of the Series D will receive, in preference to all other stockholders other than the Series E, an amount equal to the sum of the Series D original issue price, plus unpaid dividends on such shares. Next, the holders of the Series C will receive, in preference to all stockholders other than the Series E and D holders, an amount equal to the sum of the Series C original issue price plus unpaid dividends on such shares. Next, the holders of the Series B will receive, in preference to the holders of the Series A, Series A-1, Series A-2 and common stock, an amount equal to the sum of the Series B original issue price plus unpaid dividends on such shares. Next, the holders of the Series A, Series A-1, and Series A-2 will receive, in preference to the holders of common stock, an amount equal to the greater of their applicable liquidation preference or what they would have received had their shares converted into common stock. If the proceeds available are not sufficient to satisfy the full liquidation preference, the entire proceeds are to be distributed pro-rata among the Series E holders in proportion to the full preferential amount the Series E holders are entitled to receive.
Preferred stock, conversion basis					one-for-one basis
Preferred stock, conversion ratio					1
Common Stock
Temporary Equity [Line Items]
Proceeds from issuance of convertible preferred stock \| $					$ 50,000,000.0
Preferred stock, conversion price \| $ / shares					$ 1.554975
Series A Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					1,701,141	1,701,141
Convertible preferred stock, shares issued					1,701,141	1,701,141
Convertible preferred stock, shares outstanding				1,701,141	1,701,141	1,701,141		1,701,141	1,701,141	1,701,141		1,701,141	1,701,141
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Preferred stock dividends declared \| $					$ 0
Preferred stock, conversion price \| $ / shares					$ 2.00
Preferred Stock, conversion price due to anti-dilution protection terms \| $ / shares					$ 1.8191
Preferred stock, conversion ratio					1.099
Series A Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							12.47
Series A-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					3,298,732	3,298,732
Convertible preferred stock, shares issued					3,298,732	3,298,732
Convertible preferred stock, shares outstanding				3,298,732	3,298,732	3,298,732		3,298,732	3,298,732	3,298,732		3,298,732	3,298,732
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Preferred stock, conversion price \| $ / shares					2.4847
Preferred Stock, conversion price due to anti-dilution protection terms \| $ / shares					$ 2.1898
Preferred stock, conversion ratio					1.135
Series A-1 Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							12.07
Series A-2 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					4,325,021	4,325,021
Convertible preferred stock, shares issued					4,324,998	4,324,998
Convertible preferred stock, shares outstanding				4,324,998	4,324,998	4,324,998		4,324,998	4,324,998	4,324,998		4,324,998	4,324,998
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Purchase price per share \| $ / shares					$ 1.24235
Preferred stock, conversion basis					one-for-one basis
Preferred stock, conversion price \| $ / shares					$ 1.24235
Preferred stock, conversion ratio					1
Series A-2 Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							13.7
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					22,705,646	22,705,646
Convertible preferred stock, shares issued					22,531,819	22,531,819
Convertible preferred stock, shares outstanding				22,531,819	22,531,819	22,531,819		22,531,819	22,531,819	22,531,819		22,531,819	22,531,819
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Cumulative dividends \| $					$ 10,900,000
Preferred stock annual dividend rate per share \| $ / shares					$ 0.0869645
Preferred stock, conversion price \| $ / shares					$ 1.24235
Series B Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							13.7
Series C-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					58,109,711	58,109,711
Convertible preferred stock, shares issued					58,109,711	58,109,711
Convertible preferred stock, shares outstanding					58,109,711	58,109,711
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Convertible preferred stock dividend percentage					7.00%
Cumulative dividends \| $					$ 7,400,000
Preferred stock, conversion price \| $ / shares					$ 0.5213
Series C-1 Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							13.7
Series C-2 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					33,218,192	33,218,192
Convertible preferred stock, shares issued					33,218,192	33,218,192
Convertible preferred stock, shares outstanding					33,218,192	33,218,192
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Convertible preferred stock dividend percentage					7.00%
Cumulative dividends \| $					$ 3,200,000
Preferred stock, conversion price \| $ / shares					$ 0.36491
Series C-2 Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							13.7
Series D-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					57,878,742	57,878,742
Convertible preferred stock, shares issued					57,878,742	57,878,742
Convertible preferred stock, shares outstanding					57,878,742	57,878,742
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Convertible preferred stock dividend percentage					7.00%
Cumulative dividends \| $					$ 6,000,000.0
Preferred stock, conversion price \| $ / shares					$ 0.6911
Series D-1 Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							13.7
Series D-2 Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					24,598,481	24,598,481					24,598,481
Convertible preferred stock, shares issued					24,598,481	14,469,710
Convertible preferred stock, shares outstanding					24,598,481	14,469,710
Convertible preferred stock, par value \| $ / shares					$ 0.00001	$ 0.00001
Purchase price per share \| $ / shares		$ 0.6911									$ 0.6911
Issuance of convertible preferred stock, Shares		10,128,771	14,469,710
Proceeds from issuance of convertible preferred stock \| $		$ 7,000,000.0	$ 10,000,000.0
Offering costs \| $					$ 20,000.00	$ 100,000
Convertible preferred stock dividend percentage					7.00%
Cumulative dividends \| $					$ 1,000,000.0
Preferred stock, conversion price \| $ / shares					$ 0.6911
Series D-2 Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							13.7
Series E Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized					102,671,041	0
Convertible preferred stock, shares issued					102,671,041	0
Convertible preferred stock, shares outstanding				102,671,041	102,671,041	0		102,671,041
Convertible preferred stock, par value \| $ / shares	$ 0.00001				$ 0.00001	$ 0.00001
Purchase price per share \| $ / shares	$ 0.7839
Issuance of convertible preferred stock, Shares	102,671,041			102,671,041
Proceeds from issuance of convertible preferred stock \| $	$ 80,500,000				$ 80,246,000
Offering costs \| $				$ 237,000	$ 200,000
Convertible preferred stock dividend percentage					7.00%
Cumulative dividends \| $					$ 3,000,000.0
Convertible preferred stock liquidation preference \| $ / shares					$ 0.783900
Preferred stock, conversion price \| $ / shares					$ 0.7839
Series E Convertible Preferred Stock \| Subsequent Event
Temporary Equity [Line Items]
Preferred stock, conversion ratio							13.7

Common Stock - Additional Information (Details) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Common stock, shares authorized	470,183,383	232,697,999
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares issued	442,717	381,123
Common stock, shares outstanding	442,717	381,123

Series B Warrants (Tables)

9 Months Ended

Sep. 30, 2021

Equity [Abstract]

Summary of Estimated Fair Value of Warrants and Significant Assumptions

The warrants were valued using the Black-Scholes option pricing model. The estimated fair value of the warrants and the significant assumptions used were as follows:


Series B Warrants	September 30, 2021			December 30, 2021
Series B estimated fair value	$	1.12		$	1.17
Volatility		79.50	%		74.07	%
Expected term (years)		3.5			4.2
Risk free rate		0.76	%		0.27	%
Dividend yield		7.00	%		7.00	%

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2021

Prepaid Expense and Other Assets, Current [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30, 2021		December 31, 2020
Prepaid insurance	$	80	$	51
Prepaid research and development expenses		1,474		976
Other		55		16
Prepaid expenses and other current assets	$	1,609	$	1,043

Fair Value of Assets and Liabilities (Tables)

9 Months Ended

Sep. 30, 2021

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2021 and December 31, 2020 (in thousands):


Description	September 30, 2021		Quoted prices active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant other observable inputs (Level 3)
Assets
Money market funds	$	79,829	$	79,829	$	—	$	—
Total financial assets	$	79,829	$	79,829	$	—	$	—
Liability
Warrant liability	$	71	$	—	$	—	$	71
Total financial liabilities	$	71	$	—	$	—	$	71


Description	December 31, 2020		Quoted prices active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant other observable inputs (Level 3)
Liability
Warrant liability	$	72	$	—	$	—	$	72
Total financial liabilities	$	72	$	—	$	—	$	72

Summary of Changes in Fair Value of Warrants

The following table set forth a summary of changes in the fair value of the Series B Warrants, which represents a recurring fair value measurement that is classified within Level 3 of the fair value hierarchy. Changes in fair value are recognized in other (expense) income as “Change in fair value of warrant liability” in the Company’s condensed statements of operations and comprehensive loss (in thousands):


Series B Warrants (173,827 warrants)
Fair value at December 31, 2020	$	72
Change in fair value		(1	)
Fair value at September 30, 2021	$	71

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Nov. 19, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	AURA BIOSCIENCES, INC.
Entity Central Index Key	0001501796
Entity File Number	001-40971
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0271970
Entity Address, Address Line One	85 Bolton Street
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02140
City Area Code	617
Local Phone Number	500-8864
Entity Interactive Data Current	Yes
Entity Current Reporting Status	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Common Stock, par value $0.00001 per share
Trading Symbol	AURA
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Common Stock, Shares Outstanding		29,210,549

Fair Value of Assets and Liabilities

9 Months Ended

Sep. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value of Assets and Liabilities

3. Fair Value of Assets and Liabilities


Description	September 30, 2021		Quoted prices active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant other observable inputs (Level 3)
Assets
Money market funds	$	79,829	$	79,829	$	—	$	—
Total financial assets	$	79,829	$	79,829	$	—	$	—
Liability
Warrant liability	$	71	$	—	$	—	$	71
Total financial liabilities	$	71	$	—	$	—	$	71


Description	December 31, 2020		Quoted prices active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant other observable inputs (Level 3)
Liability
Warrant liability	$	72	$	—	$	—	$	72
Total financial liabilities	$	72	$	—	$	—	$	72

At September 30, 2021, the Company’s cash equivalents include investments in money market funds that invest in U.S. Treasury obligations and government funds, the fair value of which is valued using level 1 inputs. The fair value of the warrant liability was determined based on Level 3 inputs and utilizing the Black-Scholes option pricing model (see Note 10). Significant changes to these assumptions would result in increases or decreases to the fair value of the warrant liability.

During the nine months ended September 30, 2021 and 2020, there were no transfers into or out of Level 3.


Series B Warrants (173,827 warrants)
Fair value at December 31, 2020	$	72
Change in fair value		(1	)
Fair value at September 30, 2021	$	71

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitment and Contingencies

9 Months Ended

Sep. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

12. Commitments and Contingencies

Lease Commitments

The Company has historically entered into lease arrangements for its facilities. As of December 31, 2020, the Company had one operating lease for its office and laboratory facility with required future minimum payments. The lease does not contain any options to renew, terminate, or purchase the underlying asset, and was set to expire on July 31, 2022. As part of its adoption of ASC 842, the Company recorded a right-of-use asset and operating lease liability for this lease as of the effective date.

On March 31, 2021, the Company executed an amendment to the facility lease which included an extension of the expiration date of the original leased premises, the addition of 4,516 square feet of laboratory space with an expected commencement date of May 1, 2021, and the addition of 1,000 square feet of laboratory space with an expected commencement date of June 15, 2021. The lease term for the original and new spaces will expire on July 31, 2023, with an option to renew for an additional 12 months.

Upon the execution of the amendment, which was deemed to be a lease modification, the Company re-evaluated the assumptions made at the original lease commencement date. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to the modification of term for the original space, and the other is related to a new right-of-use for the two additional spaces, which are to be accounted for as new leases. The Company remeasured the lease liability and corresponding right-of-use asset for the original space as of the effective date of the amendment to reflect the extended term and recorded in the second quarter of 2021 an additional right-of-use asset and lease liability upon lease commencement of each of the additional space.

The Company also leases office and laboratory equipment for which the related expense is immaterial.


	Three Months Ended September 30, 2021		Nine Months Ended September 30, 2021
Lease Cost
Financing lease costs:
Amortization of finance right-of-use assets	$	-	$	11
Operating lease costs		154		370
Variable lease costs		90		233
Total lease costs	$	244	$	614


Cash paid for amounts included in the measurement of lease liability—finance leases	$	15
Cash paid for amounts included in the measurement of lease liability—operating leases	$	367
Weighted-average remaining lease term—operating leases (years)		1.83
Weighted-average discount rate—finance leases		7.94	%
Weighted-average discount rate—operating leases		3.51	%

The following table reconciles the future minimum commitments to the Company’s operating lease liabilities at September 30, 2021 (in thousands):


	Operating lease payments as of September 30, 2021
2021 (excluding nine months ended September 30, 2021)	$	153
2022		625
2023		377
Total lease payments		1,155
Less: interest		(35	)
Total operating lease liabilities at September 30, 2021		1,120
Less: current portion of lease liabilities		607
Lease liabilities, net of current portion	$	513

In May 2021, the Company paid in full its finance lease.

Laser Purchasing Commitment

On April 5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of €0.2 million each. The first two installments of €0.2 million were paid by the Company in April 2019 and August 2019. Upon receipt of the laser systems, the Company will assess whether the laser systems have an alternative future use and, if so, will capitalize the lasers as a component of fixed assets.

License Agreements

The Company has entered into the following key agreements that relate to the core technology under development:

LI-COR Exclusive License and Supply Agreement

In January 2014, the Company entered into an Exclusive License and Supply Agreement, or the LI-COR Exclusive License Agreement, with LI-COR, Inc., or LI-COR, for the license of IRDye 700DX and related licensed patents for the treatment and diagnosis of ocular cancers in humans, and as amended in January 2016, July 2017, April 2018 and April 2019. LI-COR is a related party owning shares of the Company’s capital stock. The LI-COR Exclusive License Agreement required a one-time upfront license issue fee of $0.1 million and requires aggregate milestone payments of up to $0.2 million upon certain regulatory and development milestones. The Company is also required to pay LI-COR low-single digit royalties on net sales. The term of the LI-COR Exclusive Agreement expires on a country-by-country basis, until the longer of (i) ten years from the first commercial sale of a licensed product in such country and (ii) the last to expire valid claim in such country. The Company recognized no expenses related to this agreement and related amendments for the nine months ended September 30, 2021 and 2020, respectively.

LI-COR Non-Exclusive License and Supply Agreement

In December 2014, the Company entered into a Non-Exclusive License Agreement, or the 2014 Non-Exclusive Agreement, for LI-COR to supply IRDye 700DX to the Company for the treatment and diagnosis of non-ocular cancers in humans. Under the 2014 Non-Exclusive Agreement, the Company paid a license issue fee of $0.03 million on the effective date. The Company must also pay LI-COR a non-refundable, non-creditable fee of $0.03 million per each licensed product upon pre-IND designation, as defined, of such licensed product. During the term, the Company must pay LI-COR low-single digit royalties on net sales. LI-COR receives 10% of all sublicensee income within 30 days of the Company’s receipt from the sublicensee. The 2014 Non-Exclusive Agreement also required the Company to make certain payments upon the achievement of specified development and commercial milestones of up to $0.4 million in the aggregate.

Life Technologies Corporation

In December 2014, the Company entered into a non-exclusive, perpetual license agreement with Life Technologies Corporation, or Life Technologies, which allows the use of their HEK293 cell lines to manufacture Aura’s products. Under this agreement the Company is required to pay an initial license fee of $0.1 million for each product. An annual development fee of $0.1 million is due within a year from the payment of the initial license fee and due annually until the earlier of (i) payment of a commercialization fee or (ii) all development work is terminated. The commercialization fee is a one-time, non-refundable, non-creditable fee of $0.3 million due upon receipt of approval of a licensed product. In the event of a change of control of an above 50% change in voting share, there will be a change of control fee of $0.2 million. The Company recorded a derivative liability due an increased probability of payment assessed in June 2021 to account for the change of control fee. Such amount was reduced to nil during the three months ended September 30, 2021 as the probability of a change of ownership above 50% of voting shares for the pending IPO was deemed probable not to occur. During the nine months ended September 30, 2021 and 2020, the Company recognized $0.03 million of expenses related to this agreement.

National Institute of Health (NIH)-Biologic Materials License Agreement

In December 2010, the Company entered into a Biologic Materials License Agreement with National Institutes of Health, or the NIH, for a non-exclusive right to use materials described in Schiller et al., Virology 2004 Apr.10, 321(2):205-16, which required a one-time non-refundable license issuance fee of $0.02 million. No future milestone payments or royalties are due under this agreement.

National Institute of Health (NIH)-Collaboration Research and Development Agreement

In July 2011, the Company entered into a Collaboration Research and Development Agreement, or CRADA, with Dr. John Schiller at the NIH, for a period of two years with the rights to an exclusive license to all technology generated within the collaboration. Under the agreement, the Company was required to make annual payments each year to fund the research activities, with the first payment due within 30 days of the effective date and subsequent payments due within 30 days of the anniversary date. This agreement was further amended in 2012, 2013, 2014, 2015, 2016, 2018 and most recently in September of 2020. During 2011-2020, the Company paid an aggregate of $0.3 million in research collaboration fees, $0.04 million of which was paid in 2020.

In September 2020, the Company executed the seventh amendment to the CRADA agreement. In this amendment the term of this agreement is extended until September 30, 2022, and the Company paid $0.03 million on the tenth anniversary of the CRADA agreement which occurred in July of 2021.

National Institute of Health (NIH)-Exclusive Patent License Agreement

In 2013, the Company entered into an exclusive patent license agreement that required the Company to pay a license issue royalty fee of $0.1 million and reimburse the NIH for any patent expenses incurred. Under the agreement, the Company is required to make low single-digit percentage royalty payments based on specified levels of annual net sales of licensed products subject to certain specified reductions. The Company is required to make development and regulatory milestone payments up to $0.7 million in the aggregate and sales milestone payments up to $0.6 million in the aggregate. The Company is also required to pay NIH a mid-single to low teen-digit percentage of any sublicensing revenue the Company receives. Additionally, the Company’s payment obligations to NIH are subject to an annual minimum royalty payment of low five figures. As of September 30, 2021, the Company has paid NIH approximately $0.4 million in aggregate milestones under the NIH license agreement. In addition to milestones under the agreement, the Company reimburses the NIH for any patent filing costs incurred. As of September 30, 2021, the Company has reimbursed the NIH approximately $0.3 million in aggregate. The Company accrued $0.03 million and $0.02 million in patent licensing reimbursement fees as of September 30, 2021 and December 31, 2020.

In 2015, 2018 and 2019, the Company amended its exclusive patent license to include updates on the status of the commercial development and update/expand the list of licensed patents and patent applications. Each of those amendments required a $0.03 million payment that the Company paid.

Inserm

In November 2009, the Company entered into an exclusive, royalty-bearing license agreement with Inserm-Transfert of France for use of its patents. The agreement expires on a country by country basis based on the last to expire of any patent encompassed within the scope of the patent rights or 10 years from the date of the first commercial sale by the Company, whichever is later. There are potential milestone payments of €0.5 million ($0.5 million at December 31, 2020) in the aggregate associated with this agreement. The IND filing milestone of €0.01 million was accrued in 2016 and paid in 2017 by the Company. The milestones for the successful Phase I, II and III clinical trials are based on receiving a final report and achieving the primary endpoints defined in that trial and those milestones have not been achieved as of September 30, 2021. Upon the sublicense by the Company of a product for which royalties are payable under this agreement, low- to mid-single-digit royalty payments would be due by the Company. If Aura sublicenses the delivery platform for use with multiple drugs, low- to mid-teen payments on receipts would be due by the Company. The non-milestone payments in this agreement are subject to an anti-stacking clause. The Company did not incur any expense in the period ended September 30, 2021 and 2020.

Clearside

In July 2019, the Company entered into an exclusive license agreement with Clearside Biomedical, Inc., or Clearside, for the license of Clearside’s Suprachoroidal Microneedle Technology for use in the treatment of indeterminate lesions, and choroidal tumors. Upon execution of the license agreement, the Company paid Clearside an upfront payment of $0.1 million which was expensed as incurred. Under the Clearside license agreement, the Company is required to pay milestones up to $21.0 million in the aggregate to Clearside upon the achievement of specified regulatory and development milestones, and upon the achievement of certain commercial sales milestones The Company is also required to pay low single digit royalties on net sales. If the Company sublicenses a product for which royalties are payable, then the Company is required to pay the greater of 20% received or low single digit royalties on net sales. The Company has made no milestone or royalty payments as of September 30, 2021.

The Clearside license agreement expires on a country-by-country basis upon the later of the last to expire patent or ten years from the date of the first commercial sale of a product.

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (23,617)	$ (17,299)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	601	605
Change in fair value of warrant liability	(1)
Stock-based compensation expense	1,010	557
Loss on disposal of property and equipment	(3)
Operating lease expense	4
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(566)	(52)
Accounts payable	891	(1,837)
Accrued expenses and other liabilities	1,357	(2,538)
Net cash used in operating activities	(20,324)	(20,564)
Cash flows from investing activities:
Purchases of property and equipment	(1,306)	(639)
Net cash used in investing activities	(1,306)	(639)
Cash flows from financing activities:
Proceeds from exercise of stock options	305	148
Payments made for deferred offering/financing costs	(1,416)
Other		(25)
Net cash provided by financing activities	86,117	4,903
Net increase (decrease) in cash, cash equivalents and restricted cash	64,487	(16,300)
Cash, cash equivalents and restricted cash at beginning of period	17,487	32,543
Cash, cash equivalents and restricted cash at end of period	81,974	16,243
Supplemental Disclosure of Cash Flow Information:
Purchases of property and equipment in accounts payable and accrued expenses and other liabilities	159
Initial measurement of right-of-use assets and lease liabilities for operating lease	536
Remeasurement of right-of-use assets and lease liabilities for lease modification	390
Right-of-use assets obtained in exchange for operating lease liabilities	516
Series D Convertible Preferred Stock
Cash flows from financing activities:
Advanced proceeds from issuance of Series D convertible preferred stock, net of issuance costs		4,849
Proceeds from issuance of convertible preferred stock, net of issuance costs	6,982
Payments made for deferred offering/financing costs		$ (69)
Series E Convertible Preferred Stock
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs	$ 80,246

Description of Business

9 Months Ended

Sep. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

1. Description of Business

Aura Biosciences, Inc. is a clinical-stage biotechnology company leveraging its novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Within these condensed financial statements, unless the context otherwise requires, references to the Company or Aura refer to Aura Biosciences, Inc. The Company’s proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. The Company’s VDCs are largely agnostic to tumor type and can recognize a surface marker, known as HSPGs, that are specifically modified and more broadly expressed on many tumors. The Company is developing AU-011, its first VDC product candidate for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The Company is also developing AU-011 for additional ocular oncology indications and in non-muscle invasive bladder cancer. Aura’s team combines expertise in cancer cell biology, ophthalmology, and targeted therapies together with experience in the development and commercialization of orphan products for significant unmet medical needs. Aura’s headquarters are located in Cambridge, Massachusetts.

The Company’s operations to date have consisted primarily of conducting research and development and raising capital.

The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, the successful development and commercialization of products, fluctuations in operating results and financial risks, need for additional financing or alternative means of financial support or both to fund its current operating plan, protection of proprietary technology and patent risks, compliance with government regulations, dependence on key personnel and collaborative partners, competition, customer demand, management of growth, and the effectiveness of marketing by the Company.

Liquidity and Going Concern

Through September 30, 2021, the Company has funded its operations primarily with proceeds from the initial closing and additional closings of its convertible preferred stock financings. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of $23.6 million and $17.3 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, the Company had cash and cash equivalents of $82.0 million and an accumulated deficit of $140.5 million. The Company expects to continue to generate operating losses for the foreseeable future.

On November 2, 2021, the Company completed its initial public offering, or the IPO, in which it issued and sold 6,210,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares at a price to the public of $14.00 per share for aggregate gross proceeds of $86.9 million. The Company received approximately $77.9 million in net proceeds after deducting underwriting discounts, commissions and estimated offering expenses.

As of November 24, 2021, the issuance date of these condensed financial statements, the Company expects that its cash and cash equivalents and total net proceeds from the IPO of $77.9 million will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these condensed financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.

Impact of COVID-19

In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced. Since then, COVID-19 coronavirus has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the U.S. government- imposed travel restrictions on travel between the United States, Europe and certain other countries. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as certain worker shortages have occurred, supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain.

The Company is monitoring the potential impact of COVID-19 on its business and condensed financial statements. The effects of the public health directives and the Company’s work-from-home policies may negatively impact productivity, disrupt its business, and delay clinical programs and timelines and future clinical trials, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on its ability to conduct business in the ordinary course. These and similar, and perhaps more severe, disruptions in the Company’s operations could negatively impact business, results of operations and financial condition, including its ability to obtain financing.

To date, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and are not aware of any specific related event or circumstance that would require the Company to revise its estimates reflected in the condensed financial statements.

The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business and prospects. The extent to which the COVID-19 pandemic will directly or indirectly impact its business, results of operations, financial condition, and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects.

Related Parties

9 Months Ended

Sep. 30, 2021

Related Parties

15. Related Parties

During the nine months ended September 30, 2021 and 2020, the Company incurred $0.4 million and $0.3 million in expenses to a stockholder that provided research and development related services. Of these amounts, $0.01 and $0.1 million were in accrued expenses as of September 30, 2021 and 2020.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

On January 15, 2009, the Company’s Board adopted the 2009 Long-Term Incentive Stock Option Plan (the “2009 Plan”) for the issuance of stock-based compensation to both employees and non- employees. The awards under this plan typically vest over a 24, 36 or 48-month period, depending on the option agreement and have a 10-year term. On December 12, 2018, the 2009 Plan expired, and the Company adopted the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the “2018 Plan” and collectively with the 2009 Plan, the "Plans”). No options were modified in conjunction with the expiration of the 2009 Plan. The options granted under the 2009 Plan continue to be outstanding in accordance with their original terms. The 2018 Plan will expire in 2028. Under the 2018 Plan, Aura may grant incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and stock rights.

The Board is authorized to administer the 2018 Plan. In accordance with the provisions of the 2018 Plan, the Board determines the terms of Aura options and other awards issued pursuant thereto, including the following:



which employees, directors and consultants shall be granted awards;



the number of shares of common stock subject to options and other awards;



the exercise price of each option, which generally shall not be less than fair market value of the common stock on the date of grant;



the termination or cancellation provisions applicable to options;



the terms and conditions of other awards, including conditions for repurchase, termination or cancellation, issue price and repurchase price; and



all other terms and conditions upon which each award may be granted in accordance with the 2018 Plan.

In addition, the Board or any committee to which the Board delegates authority may, with the consent of the affected plan participants, re-price or otherwise amend outstanding awards consistent with the terms of the 2018 Plan. On March 18, 2021, the Board approved an increase to the 2018 Plan available option pool of 2,346,228 options. With this increase and the transfer of the available options from the 2009 Plan, there were 650,795 options available for grant under the 2018 Plan at September 30, 2021.

The following table summarizes the combined stock option activity under the 2009 and the 2018 Plan for the nine months ended September 30, 2021:


	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2020		1,512,129		$	3.84		7.77	$	1,174
Granted		1,883,480			6.13		-		-
Exercised		(61,594	)		4.95		-		-
Cancelled or forfeited		(169,066	)		4.50		-		-
Outstanding at September 30, 2021		3,164,949		$	5.15		8.60	$	14,053
Exercisable at September 30, 2021		1,024,453		$	3.85		6.75	$	5,849

The weighted-average grant date fair value of stock options granted during the nine months ended September 30, 2021 and 2020 is $3.97 and $2.74 per share, respectively. The total intrinsic value of options exercised was $0.01 million and $0.02 million for the nine months ended September 30, 2021 and 2020, respectively.

The Company has elected to use the Black-Scholes option pricing model to determine the fair value of options granted and generally recognizes the compensation cost of stock-based awards on a straight-line basis over the vesting period of the award.

The determination of the fair value of stock-based payment awards utilizing the Black-Scholes option pricing model is affected by the estimated fair value of the Company’s common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate, and expected dividends.

The fair value of the stock options issued for the three and nine months ended September 30, 2021 and 2020 was measured with the following weighted-average assumptions:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Weighted average risk-free interest rate		1.00	%		0.33	%		1.06	%		0.58	%
Expected term (years)		6.06			5.67			6.02			6.03
Expected volatility		73.36	%		73.71	%		74.21	%		74.16	%
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

The Company recorded stock-based compensation expense as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Research and development	$	157	$	47	$	263	$	153
General and administrative		397		144		747		404
Total	$	554	$	191	$	1,010	$	557

As of September 30, 2021, there was $7.9 million of unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.61 years.

Common Stock

9 Months Ended

Sep. 30, 2021

Equity [Abstract]

Common Stock

8. Common Stock

The Company had 470,183,383 and 232,697,999 authorized shares of common stock, par value $0.00001 per share, of which 442,717 and 381,123 shares were issued and outstanding as of September 30, 2021 and December 31, 2020, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2021

Payables And Accruals [Abstract]

Summary of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	September 30, 2021		December 31, 2020
Accrued research and development expenses	$	1,184	$	750
Accrued compensation		1,569		1,023
Other		735		277
Accrued expenses and other current liabilities	$	3,488	$	2,050

Stock-Based Compensation - Summary of Combined Stock Option Activity under 2009 and 2018 Plan (Details) - 2009 and 2018 Plan $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance \| shares	1,512,129
Options, Granted \| shares	1,883,480
Options, Exercised \| shares	(61,594)
Options, Cancelled or forfeited \| shares	(169,066)
Options Outstanding, Ending balance \| shares	3,164,949	1,512,129
Options, Exercisable at September 30, 2021 \| shares	1,024,453
Weighted Average Exercise Price, Beginning balance \| $ / shares	$ 3.84
Weighted Average Exercise Price, Granted \| $ / shares	6.13
Weighted Average Exercise Price, Exercised \| $ / shares	4.95
Weighted Average Exercise Price, Cancelled or forfeited \| $ / shares	4.50
Weighted Average Exercise Price, Ending balance \| $ / shares	5.15	$ 3.84
Weighted Average Exercise Price, Exercisable at September 30, 2021 \| $ / shares	$ 3.85
Weighted Average Remaining Contractual Term (years)	8 years 7 months 6 days	7 years 9 months 7 days
Weighted Average Remaining Contractual Term (years), Exercisable	6 years 9 months
Aggregate Intrinsic Value, Outstanding \| $	$ 14,053	$ 1,174
Aggregate Intrinsic Value, Exercisable at September 30, 2021 \| $	$ 5,849

Fair Value of Assets and Liabilities - Summary of Changes in Fair Value of Series B Warrants (Parenthetical) (Details) - shares	Sep. 30, 2021	Dec. 31, 2020
Series B Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Warrants outstanding	173,827	173,827

Income Taxes - Additional Information (Details)	9 Months Ended
Income Taxes - Additional Information (Details)	Sep. 30, 2021 USD ($)
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%
Unrecognized income tax benefits that would reduce effective tax rate if recognized	$ 0

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. In management’s opinion, the accompanying unaudited condensed financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows.

Unaudited Interim Financial Information

The accompanying condensed balance sheet as of September 30, 2021, the condensed statements of operations and comprehensive loss, condensed statement of convertible preferred stock and stockholders’ deficit for the three and nine months ended September 30, 2021 and 2020, and the condensed statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2021 and the results of its operations for the three and nine months ended September 30, 2021 and 2020 and its cash flows for the nine months ended September 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2021 and 2020 are also unaudited. The unaudited condensed results of operations are not necessarily indicative of the operating results that may occur for the full fiscal year ending December 31, 2021. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission, or the SEC. Management believes that the disclosures provided here are adequate to make the information presented not misleading when these unaudited condensed financial statements are read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2020. The balance sheet data as of December 31, 2020 was derived from the Company’s audited financial statements included in the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on November 1, 2021.

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2020, filed with the SEC as a part of the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on November 1, 2021. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies except as noted below.

Cash Equivalents

Cash equivalents are highly liquid investments with an original maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds that invest in U.S. Treasury obligations and government funds with commercial banks and financial institutions.

Leases

Prior to January 1, 2021, the Company accounted for leases in accordance with ASC 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalation, holidays and lease incentives, on a straight-line basis over the lease term. The difference between rent expense recorded and the amount paid was charged to deferred rent. The Company presented lease incentives as deferred rent and amortized the incentives as a reduction to rent expense on a straight-line basis over the lease term. The Company classified deferred rent as current and noncurrent liabilities based on the portion of the deferred rent that was scheduled to mature within the proceeding twelve months.

Effective January 1, 2021, the Company accounts for leases in accordance with ASU No. 2016-02, Leases (Topic 842) (“ASC 842”). At contract inception, the Company determines if an arrangement is or contains a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. For each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability.

The Company adopted the new leasing standard effective January 1, 2021, using the modified retrospective transition approach which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. ASC 842 provides several optional practical expedients in transition. The Company has elected to apply the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases.

A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. The Company elected the practical expedient to not separate lease and non-lease components for all classes of underlying assets and therefore measures each lease payment as the total of the fixed lease and associated non-lease components. Lease liabilities are measured at lease commencement and calculated as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. If an implicit rate is not readily determinable, the Company uses an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at the commencement date. Right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor. The lease term is measured as the noncancelable period in the contract, adjusted for any options to extend or terminate when it is reasonably certain the Company will extend the lease term via such options based on an assessment of economic factors present as of the lease commencement date. The Company elected the practical expedient to not recognize leases with a lease term of twelve months or less.

Components of a lease are split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) are allocated, based on the respective relative fair values, to the lease components and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.

The Company’s operating leases are presented in the condensed balance sheet as operating lease right-of-use assets, classified as noncurrent assets, and operating lease liabilities, classified as current and noncurrent liabilities. Operating lease expense is recognized on a straight-line basis over the lease term. Variable costs associated with a lease, such as maintenance and utilities, are not included in the measurement of the lease liabilities and right-of-use assets but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.

Deferred Offering Costs

The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible preferred stock or in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. As of September 30, 2021, the Company had deferred offering costs of $1.6 million.

Recently Adopted Accounting Pronouncements

Upon adoption of ASC 842, the Company recorded lease liabilities and their corresponding right-of-use assets based on the present value of lease payments over the remaining lease term. The adoption of ASC 842 resulted in the recognition of operating lease liabilities of $0.6 million and operating lease right-of-use assets of $0.5 million and the derecognition of deferred rent liabilities of $0.02 million on the Company’s balance sheet as of January 1, 2021. The adoption impact relates to the Company’s existing operating lease for operating and laboratory space. The adoption of ASC 842 did not have a material impact on the Company’s statements of operations and comprehensive loss or statements of cash flows.

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Convertible preferred stock, par value	$ 0.00001
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	470,183,383	232,697,999
Common stock, shares issued	442,717	381,123
Common stock, shares outstanding	442,717	381,123
Series A Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	1,701,141	1,701,141
Convertible preferred stock, shares issued	1,701,141	1,701,141
Convertible preferred stock, shares outstanding	1,701,141	1,701,141
Convertible preferred stock, liquidation preference	$ 3,403	$ 3,403
Series A-1 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	3,298,732	3,298,732
Convertible preferred stock, shares issued	3,298,732	3,298,732
Convertible preferred stock, shares outstanding	3,298,732	3,298,732
Convertible preferred stock, liquidation preference	$ 8,196	$ 8,196
Series A-2 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	4,325,021	4,325,021
Convertible preferred stock, shares issued	4,324,998	4,324,998
Convertible preferred stock, shares outstanding	4,324,998	4,324,998
Convertible preferred stock, liquidation preference	$ 5,373	$ 5,373
Series B Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	22,705,646	22,705,646
Convertible preferred stock, shares issued	22,531,819	22,531,819
Convertible preferred stock, shares outstanding	22,531,819	22,531,819
Convertible preferred stock, liquidation preference	$ 38,894	$ 37,429
Series C-1 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	58,109,711	58,109,711
Convertible preferred stock, shares issued	58,109,711	58,109,711
Convertible preferred stock, shares outstanding	58,109,711	58,109,711
Convertible preferred stock, liquidation preference	$ 37,736	$ 36,150
Series C-2 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	33,218,192	33,218,192
Convertible preferred stock, shares issued	33,218,192	33,218,192
Convertible preferred stock, shares outstanding	33,218,192	33,218,192
Convertible preferred stock, liquidation preference	$ 15,332	$ 14,697
Series D-1 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	57,878,742	57,878,742
Convertible preferred stock, shares issued	57,878,742	57,878,742
Convertible preferred stock, shares outstanding	57,878,742	57,878,742
Convertible preferred stock, liquidation preference	$ 46,003	$ 43,908
Series D-2 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	24,598,481	24,598,481
Convertible preferred stock, shares issued	24,598,481	14,469,710
Convertible preferred stock, shares outstanding	24,598,481	14,469,710
Convertible preferred stock, liquidation preference	$ 17,982	$ 10,176
Series E Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	102,671,041	0
Convertible preferred stock, shares issued	102,671,041	0
Convertible preferred stock, shares outstanding	102,671,041	0
Convertible preferred stock, liquidation preference	$ 83,525

Subsequent Events

9 Months Ended

Sep. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

16. Subsequent Events

Subsequent events have been evaluated through the date of filing of the unaudited condensed financial statements. The Company has identified the following subsequent events that require disclosure:

A. Election of Automatic Conversion of Preferred Stock

On October 7, 2021, the required convertible preferred stockholders authorized the automatic conversion of all shares of convertible preferred stock in an initial public offering, subject to the price per share of the common stock in the Company’s sale of shares of common stock to the public in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $75.0 million of gross proceeds to the Company and such shares being listed on the Nasdaq Stock Market, or a Public Offering, being at least $0.94068 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), (ii) subject to and effective upon the closing of the Public Offering and (iii) subject to the Public Offering being consummated no later than February 28, 2022.

B. Reverse Stock Split

On October 22, 2021, the Company effected a reverse stock split of the Company’s common stock on a 1-for-13.7 basis, or the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company’s convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. Accordingly, all common stock share and per share amounts, for all periods presented in these condensed financial statements, have been retroactively adjusted, to reflect this reverse stock split and adjustment of the convertible preferred stock conversion ratios.

C. Initial Public Offering

On November 2, 2021, the Company completed its IPO, in which it issued and sold 6,210,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares at a price to the public of $14.00 per share for aggregate gross proceeds of $86.9 million. The Company received approximately $77.9 million in net proceeds after deducting underwriting discounts, commissions and estimated offering expenses.

D. 2021 Stock Option and Incentive Plan

The 2021 Stock Option and Incentive Plan, or the 2021 Plan, was adopted by the Board on October 7, 2021, approved by the Company’s stockholders on October 22, 2021 and became effective on November 1, 2021. The 2021 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code and options that do not so qualify. The number of shares initially reserved for issuance under the 2021 Plan was 3,352,166, which will automatically increase on January 1, 2022 and each January 1 thereafter, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s compensation committee. The maximum number of shares of common stock that may be issued in the form of incentive stock options shall not exceed the initial limit, cumulatively increased on January 1, 2022 and on each January 1 thereafter by the lesser of the annual increase for such year or 3,352,166 shares of common stock.

E. 2021 Employee Stock Purchase Plan

The 2021 Employee Stock Purchase Plan, or the ESPP, was adopted by the Board on October 7, 2021, approved by the Company’s stockholders on October 22, 2021 and became effective on November 1, 2021. A total of 335,217 shares of common stock were initially reserved for issuance under this plan, which will automatically increase on January 1, 2022 and each January 1 thereafter through January 1, 2031, by the least of (i) 335,217 shares of common stock, (ii) 1% of the outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the ESPP.

Description of Business - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended						9 Months Ended
	Nov. 02, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Description Of Business [Line Items]
Net losses		$ 8,838	$ 8,852	$ 5,927	$ 3,631	$ 6,156	$ 7,512	$ 23,617	$ 17,299
Cash and cash equivalents		81,974			$ 16,243			81,974	$ 16,243	$ 17,487	$ 32,543
Accumulated deficit		$ 140,503						$ 140,503		$ 116,886
Initial Public Offering \| Subsequent Event
Description Of Business [Line Items]
Share price	$ 14.00
Aggregate gross proceeds from IPO	$ 86,900
Net proceeds from the IPO	$ 77,900
Common Stock \| Initial Public Offering \| Subsequent Event
Description Of Business [Line Items]
Shares issued and sold	6,210,000

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 554	$ 191	$ 1,010	$ 557
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	157	47	263	153
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 397	$ 144	$ 747	$ 404

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Mar. 18, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options granted	$ 3.97	$ 2.74
Total intrinsic value of options exercised	$ 10	$ 20
Unrecognized compensation expense related to stock options	$ 7,900
Unrecognized compensation expense weighted average period	2 years 7 months 9 days
2009 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting description	The awards under this plan typically vest over a 24, 36 or 48-month period, depending on the option agreement
Expiration period	10 years
Expiration date	Dec. 12, 2018
2018 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized			2,346,228
Number of shares available for future issuance	650,795

Stock-Based Compensation - Schedule of Fair Value of Stock Options, Valuation Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average risk-free interest rate	1.00%	0.33%	1.06%	0.58%
Expected term (years)	6 years 21 days	5 years 8 months 1 day	6 years 7 days	6 years 10 days
Expected volatility	73.36%	73.71%	74.21%	74.16%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2021

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

6. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	September 30, 2021		December 31, 2020
Accrued research and development expenses	$	1,184	$	750
Accrued compensation		1,569		1,023
Other		735		277
Accrued expenses and other current liabilities	$	3,488	$	2,050

Compensation - Additional Information (Details) - 401(k) Plan - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Defined Contribution Plan Disclosure [Line Items]
Matching contribution by employer, percentage	100.00%
Employer matching contribution, percent of employees contribution	6.00%
Matching contributions from employer	$ 0.2	$ 0.1

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2021

Earnings Per Share [Abstract]

Summary of Basic and Diluted Net Loss Per Share

The Company has calculated basic and diluted net loss per share for the three and nine months ended September 30, 2021 and 2020 as follows (in thousands, except share and per share data):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Numerator:
Net loss	$	(8,838	)	$	(3,631	)	$	(23,617	)	$	(17,299	)
Less: Accruals of dividends of preferred stock		(3,668	)		(1,948	)		(9,627	)		(5,802	)
Net loss attributable to common stockholders—basic and diluted	$	(12,506	)	$	(5,579	)	$	(33,244	)	$	(23,101	)
Denominator:
Weighted-average common stock outstanding		441,448			376,738			426,604			362,735
Net loss per share attributable to common stockholders— basic and diluted		(28.33	)		(14.81	)		(77.93	)		(63.69	)

Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share

The following potentially dilutive securities were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been antidilutive:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Convertible preferred stock on as if converted basis		22,550,561		13,260,868		22,550,561		13,260,868
Stock options to purchase common stock		3,164,949		1,412,791		3,164,949		1,412,791
Warrants to purchase preferred stock		12,686		12,686		12,686		12,686
Total potential dilutive shares		25,728,196		14,686,345		25,728,196		14,686,345

Property and Equipment, Net

9 Months Ended

Sep. 30, 2021

Property Plant And Equipment [Abstract]

Property and Equipment, Net

4. Property and Equipment, Net

Property and equipment, net, consisted of the following (in thousands):


	September 30, 2021			December 31, 2020
Assets under construction	$	1,741		$	1,154
IT equipment		73			—
Leasehold improvements		13			—
Lab equipment		5,085			4,708
Office furniture		63			64
Total property and equipment	$	6,975		$	5,926
Less—accumulated depreciation		(2,533	)		(2,352	)
Property and equipment, net	$	4,442		$	3,574

Depreciation expense was $0.2 million for the three months ended September 30, 2021 and 2020, and was $0.6 million for the nine months ended September 30, 2021 and 2020.

Fair Value of Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Financial assets	$ 79,829
Liability
Financial liabilities	71	$ 72
Money Market Funds
Assets
Financial assets	79,829
Warrant Liability
Liability
Financial liabilities	71	72
Level 1
Assets
Financial assets	79,829
Level 1 \| Money Market Funds
Assets
Financial assets	79,829
Level 3
Liability
Financial liabilities	71	72
Level 3 \| Warrant Liability
Liability
Financial liabilities	$ 71	$ 72

Fair Value of Assets and Liabilities - Summary of Changes in Fair Value of Series B Warrants (Details) - Series B Warrants $ in Thousands	9 Months Ended
	Sep. 30, 2021 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 72
Change in fair value	(1)
Ending Balance	$ 71

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Combined Stock Option Activity under 2009 and 2018 Plan

The following table summarizes the combined stock option activity under the 2009 and the 2018 Plan for the nine months ended September 30, 2021:


	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2020		1,512,129		$	3.84		7.77	$	1,174
Granted		1,883,480			6.13		-		-
Exercised		(61,594	)		4.95		-		-
Cancelled or forfeited		(169,066	)		4.50		-		-
Outstanding at September 30, 2021		3,164,949		$	5.15		8.60	$	14,053
Exercisable at September 30, 2021		1,024,453		$	3.85		6.75	$	5,849

Schedule of Fair Value of Stock Options, Valuation Assumptions

The fair value of the stock options issued for the three and nine months ended September 30, 2021 and 2020 was measured with the following weighted-average assumptions:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Weighted average risk-free interest rate		1.00	%		0.33	%		1.06	%		0.58	%
Expected term (years)		6.06			5.67			6.02			6.03
Expected volatility		73.36	%		73.71	%		74.21	%		74.16	%
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

Summary of Stock-Based Compensation Expense

The Company recorded stock-based compensation expense as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Research and development	$	157	$	47	$	263	$	153
General and administrative		397		144		747		404
Total	$	554	$	191	$	1,010	$	557

Commitments and Contingencies - Additional Information (Details) € in Thousands			1 Months Ended								3 Months Ended	9 Months Ended			12 Months Ended
	Mar. 31, 2021 ft²	Apr. 05, 2019 EUR (€) Installment	Jul. 31, 2021 USD ($)	Aug. 31, 2019 EUR (€)	Jul. 31, 2019 USD ($)	Apr. 30, 2019 EUR (€)	Dec. 31, 2014 USD ($)	Jul. 31, 2011	Dec. 31, 2010 USD ($)	Nov. 30, 2009	Sep. 30, 2021 USD ($)	Sep. 30, 2021 EUR (€)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($) OperatingLease	Dec. 31, 2016 EUR (€)	Dec. 31, 2013 USD ($)	Jan. 31, 2014 USD ($)
Lessee Lease Description [Line Items]
Operating lease termination date	Jul. 31, 2023
Area of space leased \| ft²	4,516
Lease commencement date	May 01, 2021
Additional square feet of laboratory space \| ft²	1,000
Additional leased space commencement date	Jun. 15, 2021
Lease existence of option to extend	true
Operating lease, option to extend term	12 months
Expense related to agreement and amendments													$ 4,000
Licensed patents and patent applications													30,000.00
Upfront payment					$ 100,000
Aggregate milestones payment					$ 21,000,000.0
Royalties on net sales					20.00%
Biologic Materials License Agreement
Lessee Lease Description [Line Items]
One time non refundable license issuance fee									$ 20,000.00
Milestone payments or royalties									$ 0
Collaboration Research and Development Agreement
Lessee Lease Description [Line Items]
Expenses			$ 30,000.00
National Institute of Health
Lessee Lease Description [Line Items]
License issue royalty fee																	$ 100,000
Sales milestone payments																	600,000
Development and regulatory milestone payments																	$ 700,000
Aggregate milestones													400,000
Patent licensing reimbursement fees													30,000.00		$ 20,000.00
Aggregate reimbursed													300,000
Royalty Bearing License Agreement
Lessee Lease Description [Line Items]
Expenses													0	$ 0
License agreement term										10 years
Potential milestone payments												€ 500			500,000	€ 10
LI-COR \| LI-COR Exclusive License Agreement
Lessee Lease Description [Line Items]
License issue fee																		$ 100,000
Aggregate milestone payments																		$ 200,000
Expense related to agreement and amendments													0	0
LI-COR \| 2014 Non- Exclusive Agreement
Lessee Lease Description [Line Items]
License issue fee							$ 30,000.00
Non-refundable, Non- creditable fee							30,000.00
LI-COR \| 2014 Non- Exclusive Agreement \| Maximum
Lessee Lease Description [Line Items]
Payments for development and commercial milestones							400,000
Life Technologies Corporation
Lessee Lease Description [Line Items]
Derivative liability
Non-refundable, Non- creditable fee							300,000
Initial license fee							100,000
Annual development fee							100,000
Change of control fees							$ 200,000
Percentage of change in ownership of voting shares							50.00%
Expenses													30,000.00	$ 30,000.00
Dr. John Schiller \| Collaboration Research and Development Agreement
Lessee Lease Description [Line Items]
Agreement term								2 years
First payment due								30 days
Subsequent payments due								30 days
Aggregate research collaboration fees													$ 300,000
Research collaboration fees															$ 40,000.00
Office and Laboratory Facility
Lessee Lease Description [Line Items]
Number of operating lease \| OperatingLease															1
Operating lease termination date															Jul. 31, 2022
Laser System
Lessee Lease Description [Line Items]
Purchase agreement, commitments payable in each installment \| €		€ 200
Purchase agreement, number of payment installments \| Installment		3
Laser System \| Installment One
Lessee Lease Description [Line Items]
Purchase agreement, installment amount paid \| €						€ 200
Laser System \| Installment Two
Lessee Lease Description [Line Items]
Purchase agreement, installment amount paid \| €				€ 200

Subsequent Events - Additional Information (Details) $ / shares in Units, $ in Millions				9 Months Ended
	Nov. 02, 2021 USD ($) $ / shares shares	Oct. 22, 2021	Oct. 07, 2021 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Jan. 01, 2022 shares
Scenario Forecast \| 2021 Stock Option and Incentive Plan
Subsequent Event [Line Items]
Cumulative increase in shares of common stock					3,352,166
Scenario Forecast \| 2021 Employee Stock Purchase Plan
Subsequent Event [Line Items]
Cumulative increase in shares of common stock					335,217
Common Stock
Subsequent Event [Line Items]
Gross proceeds from issuance of convertible preferred stock \| $				$ 50.0
Subsequent Event
Subsequent Event [Line Items]
Reverse stock split, conversion ratio		0.072993
Reverse stock split description		On October 22, 2021, the Company effected a reverse stock split of the Company’s common stock on a 1-for-13.7 basis, or the Reverse Stock Split.
Subsequent Event \| 2021 Stock Option and Incentive Plan
Subsequent Event [Line Items]
Number of shares reserved for issuance			3,352,166
Common stock outstanding percentage			5.00%
Subsequent Event \| 2021 Employee Stock Purchase Plan
Subsequent Event [Line Items]
Number of shares reserved for issuance			335,217
Common stock outstanding percentage			1.00%
Subsequent Event \| Conversion of Preferred Stock
Subsequent Event [Line Items]
Share price \| $ / shares			$ 0.94068
Public offering consummated date			Feb. 28, 2022
Subsequent Event \| Conversion of Preferred Stock \| Minimum
Subsequent Event [Line Items]
Gross proceeds from issuance of convertible preferred stock \| $			$ 75.0
Initial Public Offering \| Subsequent Event
Subsequent Event [Line Items]
Share price \| $ / shares	$ 14.00
Aggregate gross proceeds from IPO \| $	$ 86.9
Net proceeds from the IPO \| $	$ 77.9
Initial Public Offering \| Subsequent Event \| Common Stock
Subsequent Event [Line Items]
Shares issued and sold	6,210,000

Net Loss Per Share

9 Months Ended

Sep. 30, 2021

Earnings Per Share [Abstract]

Net Loss Per Share

13. Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company.

The Company has calculated basic and diluted net loss per share for the three and nine months ended September 30, 2021 and 2020 as follows (in thousands, except share and per share data):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Numerator:
Net loss	$	(8,838	)	$	(3,631	)	$	(23,617	)	$	(17,299	)
Less: Accruals of dividends of preferred stock		(3,668	)		(1,948	)		(9,627	)		(5,802	)
Net loss attributable to common stockholders—basic and diluted	$	(12,506	)	$	(5,579	)	$	(33,244	)	$	(23,101	)
Denominator:
Weighted-average common stock outstanding		441,448			376,738			426,604			362,735
Net loss per share attributable to common stockholders— basic and diluted		(28.33	)		(14.81	)		(77.93	)		(63.69	)

The following potentially dilutive securities were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been antidilutive:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Convertible preferred stock on as if converted basis		22,550,561		13,260,868		22,550,561		13,260,868
Stock options to purchase common stock		3,164,949		1,412,791		3,164,949		1,412,791
Warrants to purchase preferred stock		12,686		12,686		12,686		12,686
Total potential dilutive shares		25,728,196		14,686,345		25,728,196		14,686,345

Related Parties - Additional Information (Details) - Stockholder - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Related Party Transaction [Line Items]
Expenses incurred for research and development related services	$ 400	$ 300
Accrued expense, related party	$ 10	$ 100

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 81,829	$ 17,393
Restricted cash and deposits	20	19
Prepaid expenses and other current assets	1,609	1,043
Total current assets	83,458	18,455
Restricted cash and deposits, net of current portion	125	75
Right of use assets - operating lease	1,096
Property and equipment, net	4,442	3,574
Deferred offering costs	1,583
Total Assets	90,704	22,104
Current liabilities:
Accounts payable	1,736	611
Current portion of operating lease liabilities	607
Accrued expenses and other current liabilities	3,488	2,050
Total current liabilities	5,831	2,661
Deferred rent		8
Operating lease liabilities, net of current portion	513
Warrant liability	71	72
Total Liabilities	6,415	2,741
Commitments and Contingencies (Note 12)
Stockholders’ Deficit:
Common stock, $0.00001 par value, 470,183,383 and 232,697,999 authorized at September 30, 2021 and December 31, 2020, and 442,717 and 381,123 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
Additional paid-in capital	9,488	8,173
Accumulated deficit	(140,503)	(116,886)
Total Stockholders’ Deficit	(131,015)	(108,713)
Total Liabilities, Convertible Preferred Stock, and Stockholders’ Deficit	90,704	22,104
Series A Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	3,368	3,368
Series A-1 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	7,837	7,837
Series A-2 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	5,373	5,373
Series B Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	20,806	20,806
Series C-1 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	29,353	29,353
Series C-2 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	11,746	11,746
Series D-1 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	39,686	39,686
Series D-2 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	16,889	$ 9,907
Series E Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	$ 80,246

Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss	$ (8,838)	$ (8,852)	$ (5,927)	$ (3,631)	$ (6,156)	$ (7,512)	$ (23,617)	$ (17,299)
Less: Accruals of dividends of preferred stock	(3,668)			(1,948)			(9,627)	(5,802)
Net loss attributable to common stockholders - basic and diluted	$ (12,506)			$ (5,579)			$ (33,244)	$ (23,101)
Denominator:
Weighted average common stock outstanding	441,448			376,738			426,604	362,735
Net loss per share attributable to common stockholders—basic and diluted	$ (28.33)			$ (14.81)			$ (77.93)	$ (63.69)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

Property and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2021

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net, consisted of the following (in thousands):


	September 30, 2021			December 31, 2020
Assets under construction	$	1,741		$	1,154
IT equipment		73			—
Leasehold improvements		13			—
Lab equipment		5,085			4,708
Office furniture		63			64
Total property and equipment	$	6,975		$	5,926
Less—accumulated depreciation		(2,533	)		(2,352	)
Property and equipment, net	$	4,442		$	3,574

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Statement Of Cash Flows [Abstract]
Cash and cash equivalents, end of period	$ 81,829	$ 11,302
Short-term restricted cash, end of period	20	4,866
Long-term restricted cash, end of period	125	75
Cash, cash equivalents and restricted cash at end of period	$ 81,974	$ 16,243

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid insurance	$ 80	$ 51
Prepaid research and development expenses	1,474	976
Other	55	16
Prepaid expenses and other current assets	$ 1,609	$ 1,043